Facebook Pixel

Firms Halt Nexavar Skin Cancer Study

Rate This

A late-stage study of the drug Nexavar in skin cancer patients has been halted, because the drug wasn't extending patients' overall survival rate, said California-based Onyx Pharmaceuticals Inc. and partner Bayer.

An independent data monitoring committee determined the drug wouldn't meet the study's treatment goal of improved overall survival in patients, the Associated Press reported.

The companies said they'll look more closely at the results of the skin cancer study to determine if its data has any impact on other ongoing studies of Nexavar.

Nexavar is currently approved to treat liver and advanced kidney cancer, the AP reported.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy